Company profile: Foghorn Therapeutics
1.1 - Company Overview
Company description
- Provider of targeted therapies leveraging its Gene Traffic Control platform to modulate the chromatin regulatory system, including FHD-286, an enzymatic BRG1/BRM inhibitor for AML and MDS; a selective BRM inhibitor and degrader for cancers with BRG1 mutations; and an ARID1B degrader for cancers with ARID1A mutations.
Products and services
- FHD-286: An enzymatic inhibitor that targets BRG1 and BRM to treat acute myeloid leukemia and myelodysplastic syndromes
- Gene Traffic Control® platform: A proprietary platform used for discovering and developing therapies by targeting the chromatin regulatory system
- Selective BRM inhibitor and degrader: A selective therapeutic program inhibiting and degrading BRM to target cancers with mutations in the BRG1 subunit of the BAF complex
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Foghorn Therapeutics
4D Molecular Therapeutics
HQ: United States
Website
- Description: Provider of transformative gene therapeutic products enabled by a Therapeutic Vector Evolution Platform using directed evolution to create customized viral vectors for targeted delivery. Offers R100 for retinal diseases, A101 for aerosol lung delivery, and C102 for intravenous heart muscle delivery, plus a product design & development engine and in-house GMP manufacturing and IND-enabling technical operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4D Molecular Therapeutics company profile →
Sirna Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on RNA interference (RNAi) for human disease therapy, creating RNAi-based therapies to ultimately treat patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sirna Therapeutics company profile →
Generation Bio
HQ: United States
Website
- Description: Provider of genetic medicines including iqDNA, a DNA construct designed to carry large or multiple genes to cells, potentially treating a wide range of diseases; ctLNP, a cell-targeted lipid nanoparticle delivery system for specific tissue targeting enabling personalized, redosable treatments; and RES, a rapid enzymatic synthesis process that efficiently produces highly pure DNA constructs, aiming for global access to genetic medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Generation Bio company profile →
NanoOnc
HQ: United States
Website
- Description: Provider of proprietary offerings, currently expanding operations in Madison, Wisconsin.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoOnc company profile →
EnPlusOne Biosciences
HQ: United States
Website
- Description: Provider of an ezRNA platform enabling incorporation of standard and non-standard nucleobases and their modifications, supporting installation of standard and phosphorothioated backbones, and integrating 2' modifications essential for siRNA therapeutics and novel variants. Offers 3' modifications including linkers and chain terminators for emerging RNA therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EnPlusOne Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Foghorn Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Foghorn Therapeutics
2.2 - Growth funds investing in similar companies to Foghorn Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Foghorn Therapeutics
4.2 - Public trading comparable groups for Foghorn Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →